View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

MedCap AB: 2 directors

A director at MedCap AB sold 50,000 shares at 444.000SEK and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

Speciality Pharma holding back growth

17.5% below on adj. EBITA despite strong MT+AT. Adj. EBITA down 1.7-6.1% for '24e-'26e. HOLD maintained, TP down to SEK 535 (550).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

MT+AT to drive sales growth in Q2e

Q2'24 due on 24 July. EBITDA up 1.1-2.5% for '24e-'26e. HOLD maintained, TP up to SEK 550 (455).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

Strong start to the year

Solid report with a small miss on earnings. EBITDA revised up 4.4-4.6% for '24e-'26e. HOLD maintained, TP raised to SEK 455 (405).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Adam Karlsson ... (+2)
  • Adam Karlsson
  • Erik Cassel

MedCap - Valuation and outlook no longer appealing

Valuation is no longer a reason to own Medcap... … and key growth drivers looks set to slow down Down to HOLD (Buy) with TP of SEK 220 (240)

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch